Switch theme
Sign up to access all valuation multiples
Cytek Biosciences Inc is a cell analysis solutions company advancing the next generation of cell analysis tools by leveraging novel technical approaches. Its core instruments, the Cytek Aurora and Northern Lights systems, are the first full-spectrum flow cytometers able to deliver high-resolution, high-content, and high-sensitivity cell analysis by utilizing the full spectrum of fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells. Its FSP platform addresses the inherent limitations of other technologies by providing a higher density of information with greater sensitivity, more flexibility, and increased efficiency, all at a lower cost for performance. Geographically, the company generates a majority of its revenue from the United States.
2014
648
LTM Revenue $199M
LTM EBITDA $17.5M
$102M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Cytek Biosciences has a last 12-month revenue (LTM) of $199M and a last 12-month EBITDA of $17.5M.
In the most recent fiscal year, Cytek Biosciences achieved revenue of $200M and an EBITDA of -$10.0M.
Cytek Biosciences expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Cytek Biosciences valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $199M | XXX | $200M | XXX | XXX | XXX |
| Gross Profit | $110M | XXX | $111M | XXX | XXX | XXX |
| Gross Margin | 55% | XXX | 55% | XXX | XXX | XXX |
| EBITDA | $17.5M | XXX | -$10.0M | XXX | XXX | XXX |
| EBITDA Margin | 9% | XXX | -5% | XXX | XXX | XXX |
| EBIT | $4.9M | XXX | -$20.5M | XXX | XXX | XXX |
| EBIT Margin | 2% | XXX | -10% | XXX | XXX | XXX |
| Net Profit | -$10.0M | XXX | -$6.0M | XXX | XXX | XXX |
| Net Margin | -5% | XXX | -3% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Cytek Biosciences's stock price is $3.
Cytek Biosciences has current market cap of $352M, and EV of $102M.
See Cytek Biosciences trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $102M | $352M | XXX | XXX | XXX | XXX | $0.02 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Cytek Biosciences has market cap of $352M and EV of $102M.
Cytek Biosciences's trades at 0.5x EV/Revenue multiple, and -10.2x EV/EBITDA.
Equity research analysts estimate Cytek Biosciences's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Cytek Biosciences has a P/E ratio of -35.1x.
See valuation multiples for Cytek Biosciences and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $352M | XXX | $352M | XXX | XXX | XXX |
| EV (current) | $102M | XXX | $102M | XXX | XXX | XXX |
| EV/Revenue | 0.5x | XXX | 0.5x | XXX | XXX | XXX |
| EV/EBITDA | 5.8x | XXX | -10.2x | XXX | XXX | XXX |
| EV/EBIT | 21.1x | XXX | -5.0x | XXX | XXX | XXX |
| EV/Gross Profit | 0.9x | XXX | n/a | XXX | XXX | XXX |
| P/E | -35.1x | XXX | -58.5x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | 4.7x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialCytek Biosciences's last 12 month revenue growth is 2%
Cytek Biosciences's revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $0.2M for the same period.
Cytek Biosciences's rule of 40 is 0% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Cytek Biosciences's rule of X is 15% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Cytek Biosciences and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 2% | XXX | 3% | XXX | XXX | XXX |
| EBITDA Margin | 9% | XXX | -5% | XXX | XXX | XXX |
| EBITDA Growth | -11% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | 0% | XXX | -3% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 15% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.3M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 25% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 20% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 66% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Philips | XXX | XXX | XXX | XXX | XXX | XXX |
| Perspective Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| SmartVest | XXX | XXX | XXX | XXX | XXX | XXX |
| InfuSystem | XXX | XXX | XXX | XXX | XXX | XXX |
| Myomo | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Cytek Biosciences acquired XXX companies to date.
Last acquisition by Cytek Biosciences was XXXXXXXX, XXXXX XXXXX XXXXXX . Cytek Biosciences acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Cytek Biosciences founded? | Cytek Biosciences was founded in 2014. |
| Where is Cytek Biosciences headquartered? | Cytek Biosciences is headquartered in United States of America. |
| How many employees does Cytek Biosciences have? | As of today, Cytek Biosciences has 648 employees. |
| Who is the CEO of Cytek Biosciences? | Cytek Biosciences's CEO is Dr. Wenbin Jiang, PhD. |
| Is Cytek Biosciences publicy listed? | Yes, Cytek Biosciences is a public company listed on NAS. |
| What is the stock symbol of Cytek Biosciences? | Cytek Biosciences trades under CTKB ticker. |
| When did Cytek Biosciences go public? | Cytek Biosciences went public in 2021. |
| Who are competitors of Cytek Biosciences? | Similar companies to Cytek Biosciences include e.g. Philips, Perspective Therapeutics, SmartVest, InfuSystem. |
| What is the current market cap of Cytek Biosciences? | Cytek Biosciences's current market cap is $352M |
| What is the current revenue of Cytek Biosciences? | Cytek Biosciences's last 12 months revenue is $199M. |
| What is the current revenue growth of Cytek Biosciences? | Cytek Biosciences revenue growth (NTM/LTM) is 2%. |
| What is the current EV/Revenue multiple of Cytek Biosciences? | Current revenue multiple of Cytek Biosciences is 0.5x. |
| Is Cytek Biosciences profitable? | Yes, Cytek Biosciences is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Cytek Biosciences? | Cytek Biosciences's last 12 months EBITDA is $17.5M. |
| What is Cytek Biosciences's EBITDA margin? | Cytek Biosciences's last 12 months EBITDA margin is 9%. |
| What is the current EV/EBITDA multiple of Cytek Biosciences? | Current EBITDA multiple of Cytek Biosciences is 5.8x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
